References

REFERENCES

1. Karch, SB. A Brief History of Cocaine, 2nd ed, CRC Press, Boca Raton, FL 2006.
   
2. Montoya, ID, Chilcoat, HD. Epidemiology of coca derivatives use in the Andean region: a tale of five countries. Subst Use Misuse 1996; 31:1227.
   
3. Harper, SJ, Jones, NS. Cocaine: what role does it have in current ENT practice? A review of the current literature. J Laryngol Otol 2006; 120:808.
   
4. World Drug Report 2006. Report no. E.06.XI.10, United Nations Office on Drugs and Crime, 2006.
   
5. The State of the Drugs Problem in Europe. European Monitoring Centre for Drugs and Drug Addiction, Luxembourg, 2005.
   
6. Anthony, JC, Helzer, JE. Epidemiology of drug dependence. In: Textbook in Psychiatric Epidemiology, Tsuang, MT, Tohen, M, Zahner, GP, (Eds), Wiley-Liss, New York 1995. p. 361.
   
7. Results from the 2004 National Survey on Drug Use and Health: National Findings, Report no. SMA 05-4062, Office of Applied Studies, Substance Abuse and Mental Health Services Administration, Rockville, MD 2005.
   
8. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Drug Abuse Warning Network 2005 National Estimates of Drug-related Emergency Department Visits, DAWN Series D-29, DHHS Publication. No. (SMA) 074-4256, Rockville, MD 2007.
   
9. Levin, FR, Hess, JM, Gorelick, DA, et al. Patterns of cocaine use among cocaine-dependent outpatients. Am J Addict 1993; 2:109.
   
10. Myers, MG, Rohsenow, DJ, Monti, PM, Dey, A. Patterns of cocaine use among individuals in substance abuse treatment. Am J Drug Alcohol Abuse 1995; 21:223.
    
11. Kandel, DB, Huang, FY, Davies, M. Comorbidity between patterns of substance use dependence and psychiatric syndromes. Drug Alcohol Depend 2001; 64:233.
    
12. Anthony, JC, Warner, LA, Kessler, RC. Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: Basic findings from the National Comorbidity Survey. Experimental and Clinical Psychopharmacology 1994; 23:244.
    
13. Gorelick, DA. Progression of dependence in male cocaine addicts. Am J Drug Alcohol Abuse 1992; 18:13.
    
14. Gossop, M, Griffiths, P, Powis, B, Strang, J. Cocaine: patterns of use, route of administration, and severity of dependence. Br J Psychiatry 1994; 164:660.
    
15. Woody, GE, Cottler, LB, Cacciola, J. Severity of dependence: data from the DSM-IV field trials. Addiction 1993; 88:1573.
    
16. Gorelick, DA. The rate hypothesis and agonist substitution approaches to cocaine abuse treatment. Adv Pharmacol 1998; 42:995.
    
17. Volkow, ND, Fowler, JS, Wang, GJ. Imaging studies on the role of dopamine in cocaine reinforcement and addiction in humans. J Psychopharmacol 1999; 13:337.
    
18. Nelson, RA, Boyd, SJ, Ziegelstein, RC, et al. Effect of rate of administration on subjective and physiological effects of intravenous cocaine in humans. Drug Alcohol Depend 2006; 82:19.
    
19. Kendler, KS. Twin studies of psychiatric illness: an update. Arch Gen Psychiatry 2001; 58:1005.
    
20. Saxon, AJ, Oreskovich, MR, Brkanac, Z. Genetic determinants of addiction to opioids and cocaine. Harv Rev Psychiatry 2005; 13:218.
    
21. Rothman, RB, Baumann, MH, Dersch, CM, et al. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 2001; 39:32.
    
22. White, FJ, Kalivas, PW. Neuroadaptations involved in amphetamine and cocaine addiction. Drug Alcohol Depend 1998; 51:141.
    
23. Dackis, CA, O'Brien, CP. Cocaine dependence: a disease of the brain's reward centers. J Subst Abuse Treat 2001; 21:111.
    
24. Hatsukami, DK, Fischman, MW. Crack cocaine and cocaine hydrochloride. Are the differences myth or reality?. JAMA 1996; 276:1580.
    
25. Karch, SB. The Pathology of Drug Abuse, 2nd ed, CRC Press, Boca Raton, FL 1996.
    
26. Estimation of Cocaine Availability, 1996-2000. US Office of National Drug Control Strategy, Washington, DC 2001.
    
27. Bono, JP. Criminalistics - " Introduction to controlled substances. In: Drug Abuse Handbook, Karch, SB (Ed), CRC Press, Boca Raton, FL 1998. p. 1-75.
    
28. Shesser, R, Jotte, R, Olshaker, J. The contribution of impurities to the acute morbidity of illegal drug use. Am J Emerg Med 1991; 9:336.
    
29. Cone, EJ, Yousefnejad, D, Hillsgrove, MJ, et al. Passive inhalation of cocaine. J Anal Toxicol 1995; 19:399.
    
30. Kavanagh, KT, Maijub, AG, Brown, JR. Passive exposure to cocaine in medical personnel and its effect on urine drug screening tests. Otolaryngol Head Neck Surg 1992; 107:363.
    
31. Le, SD, Taylor, RW, Vidal, D, et al. Occupational exposure to cocaine involving crime lab personnel. J Forensic Sci 1992; 37:959.
    
32. Mott, SH, Packer, RJ, Soldin, SJ. Neurologic manifestations of cocaine exposure in childhood. Pediatrics 1994; 93:557.
    
33. Mirchandani, HG, Mirchandani, IH, Hellman, F, et al. Passive inhalation of free-base cocaine'crack'smoke by infants. Arch Pathol Lab Med 1991; 115:494.
    
34. Fowler, JS, Volkow, ND, Wang, GJ, et al. [(11)]Cocaine: PET studies of cocaine pharmacokinetics, dopamine transporter availability and dopamine transporter occupancy. Nucl Med Biol 2001; 28:561.
    
35. Nakahara, Y. Hair analysis for abused and therapeutic drugs. J Chromatogr B Biomed Sci Appl 1999; 733:161.
    
36. Kidwell, DA, Holland, JC, Athanaselis, S. Testing for drugs of abuse in saliva and sweat. J Chromatogr B Biomed Sci Appl 1998; 713:111.
    
37. Skopp, G, Potsch, L. Perspiration versus saliva--basic aspects concerning their use in roadside drug testing. Int J Legal Med 1999; 112:213.
    
38. Transfer of drugs and other chemicals into human milk. Pediatrics 2001; 108:776.
    
39. Nice, FJ, Snyder, JL, Kotansky, BC. Breastfeeding and over-the-counter medications. J Hum Lact 2000; 16:319.
    
40. Ostrea, EM Jr. Testing for exposure to illicit drugs and other agents in the neonate: a review of laboratory methods and the role of meconium analysis. Curr Probl Pediatr 1999; 29:37.
    
41. Caplan, YH, Goldberger, BA. Alternative specimens for workplace drug testing. J Anal Toxicol 2001; 25:396.
    
42. Cone, EJ. Pharmacokinetics and pharmacodynamics of cocaine. J Anal Toxicol 1995; 19:459.
    
43. Jenkins, AJ, Cone, EJ. Pharmacokinetics: drug absorption, distribution, and elimination. In: Drug Abuse Handbook, Karch, SB, (Ed), CRC Press, Boca Raton, FL 1998. p. 151.
    
44. Warner, A, Norman, AB. Mechanisms of cocaine hydrolysis and metabolism in vitro and in vivo: a clarification. Ther Drug Monit 2000; 22:266.
    
45. Gorelick, DA. Enhancing cocaine metabolism with butyrylcholinesterase as a treatmentstrategy. Drug Alcohol Depend 1997; 48:159.
    
46. Cone, EJ, Tsadik, A, Oyler, J, Darwin, WD. Cocaine metabolism and urinary excretion after different routes of administration. Ther Drug Monit 1998; 20:556.
    
47. Cami, J, Farre, M, Gonzalez, ML, et al. Cocaine metabolism in humans after use of alcohol. Clinical and research implications. Recent Dev Alcohol 1998; 14:437.
    
48. Hart, CL, Jatlow, P, Sevarino, KA, McCance-Katz, EF. Comparison of intravenous cocaethylene and cocaine in humans. Psychopharmacology (Berl) 2000; 149:153.
    
49. Angrist, B. Clinical effects of central nervous system stimulants: A selective update. In: Brain Reward Systems and Abuse, Engel, J, Oreland, L, Ingvar, DH, et al (Eds). Raven Press, New York 1987. p. 109-27.
    
50. Baselt, RC. Drug Effects on Psychomotor Performance. Biomedical Publications, Foster City, CA 2001.
    
51. Fischman, MW, Foltin, RW. Cocaine self-administration research: implications for rational pharmacotherapy. In: Behavior, Pharmacology, and Clinical Applications, Higgins, ST, Katz, JL (Eds). Cocaine Abuse Academic Press, San Diego, CA 1998. p. 181-207.
    
52. Blaho, K, Logan, B, Winbery, S, et al. Blood cocaine and metabolite concentrations, clinical findings, and outcome of patients presenting to an ED. Am J Emerg Med 2000; 18:593.
    
53. Hando, J, Topp, L, Hall, W. Amphetamine-related harms and treatment preferences of regular amphetamine users in Sydney, Australia. Drug Alcohol Depend 1997; 46:105.
    
54. Williamson, S, Gossop, M, Powis, B, et al. Adverse effects of stimulant drugs in a community sample of drug users. Drug Alcohol Depend 1997; 44:87.
    
55. Rosse, RB, Fay-McCarthy, M, Collins, JP Jr, et al. Transient compulsive foraging behavior associated with crack cocaine use. Am J Psychiatry 1993; 150:155.
    
56. Koob, GF. Drug addiction: the yin and yang of hedonic homeostasis. Neuron 1996; 16:893.
    
57. Schenk, S, Partridge, B. Sensitization and tolerance in psychostimulant self-administration. Pharmacol Biochem Behav 1997; 57:543.
    
58. Kollins, SH, Rush, CR. Sensitization to the cardiovascular but not subject-rated effects of oral cocaine in humans. Biol Psychiatry 2002; 51:143.
    
59. Mendelson, JH, Sholar, M, Mello, NK, et al. Cocaine tolerance: Behavioral, cardiovascular, and neuroendocrine function in men. Neuropsychopharmacology 1998; 18:263.
    
60. Ward, AS, Haney, M, Fischman, MW, Foltin, RW. Binge cocaine self-administration in humans: intravenous cocaine. Psychopharmacology (Berl) 1997; 132:375.
    
61. Perez-Reyes, M, White, WR, McDonald, SA, et al. Clinical effects of daily methamphetamine administration. Clin Neuropharmacol 1991; 14:352.
    
62. Rogers, RD, Robbins, TW. Investigating the neurocognitive deficits associated with chronic drug misuse. Curr Opin Neurobiol 2001; 11:250.
    
63. Friedman, AS, Terras, A, Zhu, W, McCallum, J. Depression, negative self-image, and suicidal attempts as effects of substance use and substance dependence. J Addict Dis 2004; 23:55.
    
64. Marzuk, PM, Tardiff, K, Leon, AC, et al. Prevalence of cocaine use among residents of New York City who committed suicide during a one-year period. Am J Psychiatry 1992; 149:371.
    
65. Wilcox, HC, Conner, KR, Caine, ED. Association of alcohol and drug use disorders and completed suicide: an empirical review of cohort studies. Drug Alcohol Depend 2004; 76 Suppl:S11.
    
66. Wines, JD Jr, Saitz, R, Horton, NJ, et al. Suicidal behavior, drug use and depressive symptoms after detoxification: a 2-year prospective study. Drug Alcohol Depend 2004; 76 Suppl:S21.
    
67. Roy, A. Characteristics of cocaine-dependent patients who attempt suicide. Am J Psychiatry 2001; 158:1215.
    
68. Sofuoglu, M, Dudish-Poulsen, S, Brown, SB, Hatsukami, DK. Association of cocaine withdrawal symptoms with more severe dependence and enhanced subjective response to cocaine. Drug Alcohol Depend 2003; 69:273.
    
69. Karmochkine, M, Carrat, F, Dos Santos, O, et al. A case-control study of risk factors for hepatitis C infection in patients with unexplained routes of infection. J Viral Hepat 2006; 13:775.
    
70. Friedman, H, Pross, S, Klein, TW. Addictive drugs and their relationship with infectious diseases. FEMS Immunol Med Microbiol 2006; 47:330.
    
71. Hill, GE, Ogunnaike,BO, Johnson, ER. General anaesthesia for the cocaine abusing patient. Is it safe?. Br J Anaesth 2006; 97:654.
    
72. Coffey, SF, Dansky, BS, Carrigan, MH, Brady, KT. Acute and protracted cocaine abstinence in an outpatient population: a prospective study of mood, sleep and withdrawal symptoms. Drug Alcohol Depend 2000; 59:277.
    
73. Cottler, LB, Shillington, AM, Compton WM, 3rd, et al. Subjective reports of withdrawal among cocaine users: recommendations for DSM-IV. Drug Alcohol Depend 1993; 33:97.
    
74. Lago, JA, Kosten, TR. Stimulant withdrawal. Addiction 1994; 89:1477.
    
75. Khantzian, EJ, McKenna, GJ. Acute toxic and withdrawal reactions associated with drug use and abuse. Ann Intern Med 1979; 90:361.
    
76. Nademanee, K, Gorelick, DA, Josephson, MA, et al. Myocardial ischemia during cocaine withdrawal. Ann Intern Med 1989; 111:876.
    
77. Lukas, SE, Renshaw, PF. Cocaine effects on brain function. In: Cocaine Abuse: Behavior, Pharmacology, and Clinical Applications, Higgins, ST, Katz, JL, (Eds). Academic Press, San Diego, CA 1998. p. 265-87.
    
78. Boghdadi, MS, Henning, RJ. Cocaine: Pathophysiology and clinical toxicology. Heart Lung 1997; 26:466.
    
79. Brust, JC. Acute neurologic complications of drug and alcohol abuse. Neurol Clin 1998; 16:503.
    
80. Neiman, J, Haapaniemi, HM, Hillbom, M. Neurological complications of drug abuse: pathophysiological mechanisms. Eur J Neurol 2000; 7:595.
    
81. Kilts, CD, Schweitzer, JB, Quinn, CK, et al. Neural activity related to drug craving in cocaine addiction. Arch Gen Psychiatry 2001; 58:334.
    
82. Mena, JC, Cuellar, H, Vargas, D, Riascos, R. PET and SPECT in drug and substance abuse. Top Magn Reson Imaging 2005; 16:253.
    
83. Kaufman, MJ, Levin, JM, Maas, LC, et al. Cocaine-induced cerebral vasoconstriction differs as a function of sex and menstrual cycle phase. Biol Psychiatry 2001; 49:774.
    
84. Westover, AN, McBride, S, Haley, RW. Stroke in young adults who abuse amphetamines or cocaine: a population-based study of hospitalized patients. Arch Gen Psychiatry 2007; 64:495.
    
85. Rojas, R, Riascos, R, Vargas, D, et al. Neuroimaging in drug and substance abuse part I: cocaine, cannabis, and ecstasy. Top Magn Reson Imaging 2005; 16:231.
    
86. Magalhaes, AC. Functional magnetic resonance and spectroscopy in drug and substance abuse. Top Magn Reson Imaging 2005; 16:247.
    
87. Warner, EA. Cocaine abuse. Ann Intern Med 1993; 119:226.
    
88. van Harten, PN, van Trier, JC, Horwitz, EH, et al. Cocaine as a risk factor for neuroleptic-induced acute dystonia. J Clin Psychiatry 1998; 59:128.
    
89. Ghuran, A, Nolan, J. Recreational drug misuse: issues for the cardiologist. Heart 2000; 83:627.
    
90. Lange, RA, Hillis, LD. Cardiovascular complications of cocaine use. N Engl J Med 2001; 345:351.
    
91. Qureshi, AI, Suri, FK, Guterman, LR, Hopkins, LN. Cocaine use and the likelihood of nonfatal myocardial infarction and stroke. Circulation 2001; 103:502.
    
92. Brecklin, CS, Gopaniuk-Folga, A, Kravetz, T, et al. Prevalence of hypertension in chronic cocaine users. Am J Hypertens 1998; 11:1279.
    
93. Givens, ML, Wald, R, Schafer, J, et al. Prevalence of cocaine use in ED patients with severe hypertension. Am J Emerg Med 2007; 25:612.
    
94. Vupputuri, S, Batuman, V, Muntner, P, et al. The risk for mild kidney function decline associated with illicit drug use among hypertensive men. Am J Kidney Dis 2004; 43:629.
    
95. Norris, KC, Thornhill-Joynes, M, Robinson, C, et al. Cocaine use, hypertension, and end-stage renal disease. Am J Kidney Dis 2001; 38:523.
    
96. Darke, S, Kaye, S, Duflou, J. Comparative cardiac pathology among deaths due to cocaine toxicity, opioid toxicity and non-drug-related causes. Addiction 2006; 101:1771.
    
97. Hsue, PY, McManus, D, Selby, V, et al. Cardiac arrest in patients who smoke crack cocaine. Am J Cardiol 2007; 99:822.
    
98. Chen, J, Naseem, RH, Obel, O, Joglar, JA. Habitual cocaine use is associated with high defibrillation threshold during ICD implantation. J Cardiovasc Electrophysiol 2007; 18:722.
    
99. Tashkin, DP. Airway effects of marijuana, cocaine, and other inhaled illicit agents. Curr Opin Pulm Med 2001; 7:43.
    
100. Pallasch, TJ, Joseph, CE. Oral manifestations of drug abuse. J Psychoactive Drugs 1987; 19:375.
     
101. Ponsoda, X, Bort, R, Jover, R, et al. Increased toxicity of cocaine on human hepatocytes induced by ethanol: role of GSH. Biochem Pharmacol 1999; 58:1579.
     
102. Gitman, MD, Singhal, PC. Cocaine-induced renal disease. Expert Opin Drug Saf 2004; 3:441.
     
103. Jaffe, JA, Kimmel, PL. Chronic nephropathies of cocaine and heroin abuse: a critical review. Clin J Am Soc Nephrol 2006; 1:655.
     
104. Fernandez, WG, Hung, O, Bruno, GR, et al. Factors predictive of acute renal failure and need for hemodialysis among ED patients with rhabdomyolysis. Am J Emerg Med 2005; 23:1.
     
105. Bemanian, S, Motallebi, M, Nosrati, SM. Cocaine-induced renal infarction: report of a case and review of the literature. BMC Nephrol 2005; 6:10.
     
106. Mello, NK, Mendelson, JH. Cocaine's effects on neuroendocrine systems: clinical and preclinical studies. Pharmacol Biochem Behav 1997; 57:571.
     
107. Warner, EA, Greene, GS, Buchsbaum, MS, et al. Diabetic ketoacidosis associated with cocaine use. Arch Intern Med 1998; 158:1799.
     
108. Bhinder, SK, Majithia, V. Cocaine use and its rheumatic manifestations: a case report and discussion. Clin Rheumatol 2007; 26:1192.
     
109. Macdonald, PT, Waldorf, D, Reinarman, C, Murphy, S. Heavy cocaine use and sexual behavior. J Drug Issues 1988; 18:437.
     
110. Bishai, R, Koren, G. Maternal and obstetric effects of prenatal drug exposure. Clin Perinatol 1999; 26:75.
     
111. Debooy, VD, Seshia, MM, Tenenbein, M, Casiro, OG. Intravenous pentazocine and methylphenidate abuse during pregnancy. Maternal lifestyle and infant outcome. Am J Dis Child 1993; 147:1062.
     
112. Eyler, FD, Behnke, M. Early development of infants exposed to drugs prenatally. Clin Perinatol 1999; 26:107.
     
113. Johnson, JL, Leff, M. Children of substance abusers: overview of research findings. Pediatrics 1999; 103:1085.
     
114. Plessinger, MA. Prenatal exposure to amphetamines. Risks and adverse outcomes in pregnancy. Obstet Gynecol Clin North Am 1998; 25:119.
     
115. Schama, KF, Howell, LL, Byrd, LD. Prenatal exposure to cocaine. In: Cocaine Abuse: Behavior, Pharmacology, and Clinical Applications, Higgins, ST, Katz, JL, (Eds), Academic Press, San Diego, CA 1998. p. 159-79.
     
116. Lester, BM. Prenatal cocaine exposure and child outcome: a model for the study of the infant at risk. Isr J Psychiatry Relat Sci 2000; 37:223.
     
117. Brown, RL, Leonard, T, Saunders, LA, Papasouliotis, O. A two-item conjoint screen for alcohol and other drug problems. J Am Board Fam Pract 2001; 14:95.
     
118. Midanik,LT, Zahnd, EG, Klein, D. Alcohol and drug CAGE screeners for pregnant, low-income women: the California Perinatal Needs Assessment. Alcohol Clin Exp Res 1998; 22:121.
     
119. Davis, TM, Bush, KR, Kivlahan, DR, et al. Screening for substance abuse and psychiatric disorders among women patients in a VA Health Care System. Psychiatr Serv 2003; 54:214.
     
120. Hinkin, CH, Castellon, SA, Dickson-Fuhrman, E, et al. Screening for drug and alcohol abuse among older adults using a modified version of the CAGE. Am J Addict 2001; 10:319.
     
121. Pence, BW, Gaynes, BN, Whetten, K, et al. Validation of a brief screening instrument for substance abuse and mental illness in HIV-positive patients. J Acquir Immune Defic Syndr 2005; 40:434.
     
122. Verstraete, AG. Detection times of drugs of abuse in blood, urine, and oral fluid. Ther Drug Monit 2004; 26:200.
     
123. Preston, KL, Epstein, DH, Cone, EJ, et al. Urinary elimination of cocaine metabolites in chronic cocaine users during cessation. J Anal Toxicol 2002; 26:393.
     
124. Cone, EJ, Weddington, WW Jr. Prolonged occurrence of cocaine in human saliva and urine after chronic use. J Anal Toxicol 1989; 13:65.
     
125. Choo, RE, Huestis, MA. Oral fluid as a diagnostic tool. Clin Chem Lab Med 2004; 42:1273.
     
126. Uemura, N, Nath, RP, Harkey, MR, et al. Cocaine levels in sweat collection patches vary by location of patch placement and decline over time. J Anal Toxicol 2004; 28:253.
     
127. Gambelunghe, C, Rossi, R, Ferranti, C, et al. Hair analysis by GC/MS/MS to verify abuse of drugs. J Appl Toxicol 2005; 25:205.
     
128. Felli, M, Martello, S, Marsili, R, Chiarotti, M. Disappearance of cocaine from human hair after abstinence. Forensic Sci Int 2005; 154:96.
     
129. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. American Psychiatric Association, Washington, DC 1994.
     
130. The ICD-10 Classification of Mental and Behavioral Disorders. Clinical Descriptions and Diagnostic Guidelines. World Heath Organization, Geneva 1992.
     
131. Schuckit, MA. Drug and Alcohol Abuse. A Clinical Guide to Diagnosis and Treatment, 6th ed, Springer, New York 2006.
     
132. Gill, K, Gillespie, HK, Hollister, LE. Dopamine depletion hypothesis of cocaine dependence: A test. Human Psychopharmacology 1991; 6:25.
     
133. Satel, SL, Price, LH, Palumbo, JM, et al. Clinical phenomenology and neurobiology of cocaine abstinence: a prospective inpatient study. Am J Psychiatry 1991; 148:1712.
     
134. Volkow, ND, Hitzemann, R, Wang, GJ, et al. Long-term frontal brain metabolic changes in cocaine abusers. Synapse 1992; 11:184.
     
135. Kampman, KM, Volpicelli, JR, Mulvaney, F, et al. Effectiveness of propranolol for cocaine dependence treatment may depend on cocaine withdrawal symptom severity. Drug Alcohol Depend 2001; 63:69.
     
136. Lange, RA, Cigarroa, RG, Flores, ED, et al. Potentiationof cocaine-induced coronary vasoconstriction by beta-adrenergic blockade. Ann Intern Med 1990; 112:897.
     
137. Mulvaney, FD, Alterman, AI, Boardman, CR, Kampman, K. Cocaine abstinence symptomatology and treatment attrition. J Subst Abuse Treat 1999; 16:129.
     
138. Rosenblum, A, Foote, J, Magura, S, et al. Follow-up of inpatient cocaine withdrawal for cocaine-using methadone patients. J Subst Abuse Treat 1996; 13:467.
     
139. Weiss, RD, Greenfield, SF, Mirin, SM. Intoxication and withdrawal syndromes. In: Manual of Psychiatric Emergencies, Hyman, SE, (Ed), Little, Brown & Co, Boston, MA 1994. p. 279-93.
     
140. American Psychiatric Association. Practice guideline for the treatment of patients with substance use disorders, 2nd edition. Am J Psychiatry 2006; 163 Suppl:1.
     
141. Lingford-Hughes, AR, Welch, S, Nutt, DJ. Evidence-based guidelines for the pharmacological management of substance misuse, addiction and comorbidity: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2004; 18:293.
     
142. Rawson, RA (ed). Treatment for Stimulant Use Disorders (TIPS #33). Center for Substance Abuse Treatment, Rockville, MD 1999.
     
143. Substance Abuse and Mental Health Services Administration. Treatment Episode Data Set (TEDS): 2003, Discharge from Substance Abuse Treatment Services. DASIS Series: S-30, DHHS Publication No. (SMA) 06-4139, Rockville, MD 2006. Available online at: www.oas.samhsa.gov (Accessed August 4, 2006).
     
144. Mee-Lee, D, Shulman, GD, Fishman, M, et al. ASAM Patient Placement Criteria for the Treatment of Substance-Related Disorders. 2nd edition revised. American Society of Addiction Medicine, Chevy Chase, MD 2001.
     
145. Baker, SL, Gastfriend, DR. Reliability of multidimensional substance abuse treatment matching: implementing the ASAM Patient Placement Criteria. J Addict Dis 2003; 22 Suppl 1:45.
     
146. Gastfriend, DR, Rubin, A, Sharon, E, et al. New constructs and assessments for relapse and continued use potential in the ASAM Patient Placement Criteria. J Addict Dis 2003; 22 Suppl 1:95.
     
147. Carroll, KM. Recent advances in the psychotherapy of addictive disorders. Curr Psychiatry Rep 2005; 7:329.
     
148. Crits-Christoph, P, Siqueland, L, Blaine, J, et al. Psychosocial treatments for cocaine dependence: National Institute on Drug Abuse Collaborative Cocaine Treatment Study. Arch Gen Psychiatry 1999; 56:493.
     
149. Woody, GE. Research findings on psychotherapy of addictive disorders. Am J Addict 2003; 12 Suppl 2:S19.
     
150. Knapp, WP, Soares, BG, Farrel, M, Lima, MS. Psychosocial interventions for cocaine and psychostimulant amphetamines related disorders. Cochrane Database Syst Rev 2007; :CD003023.
     
151. Simpson, DD, Joe, GW, Fletcher, BW, et al. A national evaluation of treatment outcomes for cocaine dependence. Arch Gen Psychiatry 1999; 56:507.
     
152. Zhang, Z, Friedmann, PD, Gerstein, DR. Does retention matter? Treatment duration and improvement in drug use. Addiction 2003; 98:673.
     
153. Domino, KB, Hornbein, TF, Polissar, NL, et al. Risk factors for relapse in health care professionals with substance use disorders. JAMA 2005; 293:1453.
     
154. Carroll, KM. Implications of recent research for program quality in cocaine dependence treatment. Subst Use Misuse 2000; 35:2011.
     
155. Weiss, RD, Griffin, ML, Gallop, RJ, et al. The effect of 12-step self-help group attendance and participation on drug use outcomes among cocaine-dependent patients. Drug Alcohol Depend 2005; 77:177.
     
156. Saitz, R, Horton, NJ, Larson, MJ, et al. Primary medical care and reductions in addiction severity: a prospective cohort study. Addiction 2005; 100:70.
     
157. Lima, MS, Reisser, AA, Soares, BG, Farrell, M. Antidepressants for cocaine dependence. Cochrane Database Syst Rev 2001; :CD002950.
     
158. Lima, AR, Lima, MS, Soares, BG, Farrell, M. Carbamazepine for cocaine dependence. Cochrane Database Syst Rev 2002; :CD002023.
     
159. Soares, BG, Lima, MS, Reisser, AA, Farrell, M. Dopamine agonists for cocaine dependence. Cochrane Database Syst Rev 2003; :CD003352.
     
160. Amato, L, Minozzi, S, Pani, PP, Davoli, M. Antipsychotic medications for cocaine dependence. Cochrane Database Syst Rev 2007; :CD006306.
     
161. Minozzi, S, Amato, L, Davoli, M, et al. Anticonvulsants for cocaine dependence. Cochrane Database Syst Rev 2008; :CD006754.
     
162. Carroll, KM, Fenton, LR, Ball, SA, et al. Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: a randomized placebo-controlled trial. Arch Gen Psychiatry 2004; 61:264.
     
163. Dackis, CA, Kampman, KM, Lynch, KG, et al. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 2005; 30:205.
     
164. Kampman, KM, Pettinati, H, Lynch, KG, et al. A pilot trial of topiramate for the treatment of cocaine dependence. Drug Alcohol Depend 2004; 75:233.
     
165. Gonzalez, G, Desai, R, Sofuoglu, M, et al. Clinical efficacy of gabapentin versus tiagabine for reducing cocaine use among cocaine dependent methadone-treated patients. Drug Alcohol Depend 2007; 87:1.
     
166. Elkashef, A, Vocci, F, Jr. Promising medications for the treatment of cocaine addiction. Presented at American Psychiatric Association annual meeting, San Diego, CA, May, 2007.
     
167. Shoptaw, S, Yang, X, Rotheram-Fuller, EJ, et al. Randomized placebo-controlled trial of baclofen for cocaine dependence: preliminary effects for individuals with chronic patterns of cocaine use. J Clin Psychiatry 2003; 64:1440.
     
168. Moeller, FG, Schmitz, JM, Steinberg, JL, et al. Citalopram combined with behavioral therapy reduces cocaine use: a double-blind, placebo-controlled trial. Am J Drug Alcohol Abuse 2007; 33:367.
     
169. Johnson, BA, Roache, JD, Ait-Daoud, N, et al. A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of cocaine dependence. Drug Alcohol Depend 2006; 84:256.
     
170. Montoya, ID, Gorelick, DA, Preston, KL, et al. Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence. Clin Pharmacol Ther 2004; 75:34.
     
171. Poling, J, Oliveto, A, Petry, N, et al. Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population. Arch Gen Psychiatry 2006; 63:219.
     
172. Mardikian, PN, LaRowe, SD, Hedden, S, et al. An open-label trial of N-acetylcysteine for the treatment of cocaine dependence: a pilot study. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31:389.
     
173. LaRowe, SD, Myrick, H, Hedden, S, et al. Is cocaine desire reduced by N-acetylcysteine?. Am J Psychiatry 2007; 164:1115.
     
174. Martell, BA, Mitchell, E, Poling, J, et al. Vaccine pharmacotherapy for the treatment of cocaine dependence. Biol Psychiatry 2005; 58:158.
     
175. Montoya, ID, Schroeder, JR, Preston, KL, et al. Influence of psychotherapy attendance on buprenorphine treatment outcome. J Subst Abuse Treat 2005; 28:247.
     
176. Margolin, A, Kleber, HD, Avants, SK, et al. Acupuncture for the treatment of cocaine addiction: a randomized controlled trial. JAMA 2002; 287:55.
     
177. Gates, S, Smith, LA, Foxcroft, DR. Auricular acupuncture for cocaine dependence. Cochrane Database Syst Rev 2006; :CD005192.
     
178. Mills, EJ, Wu, P, Gagnier, J, Ebbert, JO. Efficacy of acupuncture for cocaine dependence: a systematic review & meta-analysis. Harm Reduct J 2005; 2:4.
     
179. Kampman, K, Majewska, MD, Tourian, K, et al. A pilot trial of piracetam and ginkgo biloba for the treatment of cocaine dependence. Addict Behav 2003; 28:437.